PTGS2 and Alzheimer disease: Clinical trials have reported that treatment with indomethacin, a nonselective COX inhibitor, ameliorates cognitive impairment in patients with AD [110], and that naproxen, a selective COX-2 inhibitor, blocks the Aβ-mediated suppression of long-term potentiation and memory function in Tg2576 AD model mice [111].